H ypertension is a modifiable risk factor for cerebral smallvessel disease. [1] [2] [3] In animal models of hypertension, remodeling occurs in the middle cerebral artery 4 and parenchymal arterioles (PAs), 5 producing arteries with smaller lumens and thicker walls, and the same effect is observed in patients with hypertension.
H ypertension is a modifiable risk factor for cerebral smallvessel disease. [1] [2] [3] In animal models of hypertension, remodeling occurs in the middle cerebral artery 4 and parenchymal arterioles (PAs), 5 producing arteries with smaller lumens and thicker walls, and the same effect is observed in patients with hypertension. 1 However, our understanding of the mechanisms responsible for these changes in the cerebral circulation remains incomplete.
Our studies focus on 2 artery types: PAs and posterior cerebral arteries (PCAs). The PAs have a limited number of anastomoses and arise from pial arteries to perfuse the cerebral microcirculation. These arterioles play a critical role in the outcome of ischemia and the development of vascular dementia. [5] [6] [7] The PCA, a large pial artery, regulates perfusion of the hippocampus, the temporal cortex, and parts of the parieto-occipital cortex 8 which are associated with memory formation. Aldosterone and mineralocorticoid receptor (MR) activation have been linked to vascular damage in hypertension. 5, 9 However, the specific cell type involved in MR-mediated artery remodeling in the brain has not been defined. Identifying the cell type that drives the MR-mediated remodeling will allow us to define the specific cellular pathways activated by the MR, and this may allow for the development of more specific therapies to prevent or reverse cerebral vascular remodeling in hypertensive patients. Cell-specific MR knockout mice have been developed to facilitate studies defining the role played by the endothelial cell MR (EC-MR). Mueller et al 10 used a specific EC-MR knockout driven by the vascular endothelialcadherin promoter to show that the EC-MR regulates mesenteric artery vasodilation but not coronary artery function in response to hypertension. These studies suggest that EC-MR activation is an important mediator of hypertensive vascular injury. These studies also highlight the need to study the cerebral vasculature separately, not only because it is anatomically unique but also because it is clear that different vascular beds have varying sensitivities to EC-MR signaling. December 2017
In this study, we used a pharmacological and genetic approach to test the hypothesis that the EC-MR activation is required for angiotensin II (AngII)-hypertensive cerebral artery remodeling. We used eplerenone (100 mg /kg per day) 5 to pharmacologically inhibit the receptor to confirm that MR signaling mediates hypertensive remodeling of PAs and PCAs. EC-MR knockout (ECMRKO) mice generated using the vascular endothelial-cadherin promoter were used to determine whether EC-MR is involved in cerebral artery remodeling in AngII hypertension. PAs were used as a model of the cerebral microcirculation and the PCA as a model of a large cerebral resistance artery.
Methods
Materials and detailed methods are available in the online-only Data Supplement.
Animal Models
All experimental protocols were approved by the Michigan State University Animal Care and Use Committee and were performed in accordance with the American Physiological Society Guiding Principles in the Care and Use of Animals. C57Bl/6 mice (n=6-8 per group) were purchased from Charles River Laboratories. ECMRKO mice (n=6-8 per group) were generated by Dr Iris Z. Jaffe at Tufts Medical Center by crossing vascular endothelial-cadherin Cad-Cre + mice with MR f/f mice as described previously. 10,11 MR f/f mice had exons 5 and 6 of the MR gene flanked by loxP (locus of X-over P1) sites. 10, 11 These EC-MR knockouts have been shown to be specific for the endothelium with MR recombination confirmed in ECs from all vascular beds tested including lung, heart, and aorta without MR recombination in splenic leukocytes or lymph nodes and with intact MR mRNA expression in isolated leukocytes. 10, 12 MR-intact littermates were used as controls. All mice studied were males and housed on 12:12-hour light/dark cycle with food and water ad libitum.
Statistical Analyses
All data are presented as mean±SEM. Blood pressure, plasma aldosterone, mRNA expression, and cerebral perfusion data were analyzed by 1-way ANOVA. For analysis of artery structure, 2-way ANOVA with repeated measures in 1 factor (pressure) was used followed by Bonferroni adjustments for post hoc comparison. All statistical analyses were performed using GraphPad Prism 7.0 software (GraphPad, San Diego, CA). In all cases, statistical significance was denoted by P <0.05.
Results

MR Antagonism Does Not Change PA and PCA Structure Under Control Conditions
To test the possibility that under normal conditions MR activation regulates artery structure, Sham-operated mice were treated with eplerenone. MR inhibition in normotensive mice did not cause PA or PCA remodeling as evidenced by the lack of difference in the outer diameter, lumen diameter, or wall cross-sectional area when compared with Sham mice ( Figure S1 in the online-only Data Supplement). Measurements are presented at the physiological intralumenal pressure of 40 mm Hg for the PAs and 60 mm Hg for the PCA. As previously demonstrated in the aorta, 10 we confirmed that the ECMRKO mice also had decreased MR mRNA expression in the PCA when compared with the MR-intact littermates ( Figure S2 in the online-only Data Supplement). There was still some MR mRNA expression in the PCAs from the ECMRKO mice because the vascular smooth muscle cells (VSMCs) also express the receptor. Although we expect MR gene recombination in all ECs, because of insufficient tissue from the PAs, we could not measure changes in gene expression of the MR. Specific EC-MR deletion did not change the structure of the PAs or PCAs under normotensive conditions. Outer diameter, lumen diameter, and wall area were not changed when compared with MR-intact littermates ( Figure S3 in the onlineonly Data Supplement). MR inhibition and specific EC-MR deletion also did not alter cerebral perfusion as shown in the C57Bl/6 mice treated with eplerenone and the ECMRKO mice ( Figure 1 ).
AngII Increases Systolic Blood Pressure and Plasma Aldosterone
C57Bl/6 Mice To assess the role of the MR in the genesis of AngII hypertension, C57Bl/6 mice were treated with eplerenone during the 4 weeks of AngII infusion (800 ng/kg per minute). AngII treatment increased systolic blood pressure (Table S1 in the online-only Data Supplement) but eplerenone did not reduce blood pressure, suggesting that MR activation is not the major driving force for the elevation in blood pressure caused by AngII administration. As expected because of its role in activating adrenal mineralocorticoid production, AngII infusion increased plasma aldosterone levels. This was not altered by eplerenone treatment (Figure 2A ). The mice treated with AngII and the vehicle for eplerenone had a similar increase in aldosterone (Table S2 in the online-only Data Supplement). Plasma corticosterone levels remained unchanged in all groups ( Figure 2C ).
ECMRKO Mice
As previously reported, 10 EC-MR-specific deletion is not associated with changes in baseline blood pressure (Table S1 in the online-only Data Supplement). ECMRKO mice were infused with AngII and compared with MR-intact littermates with AngII treatment or Sham surgery. AngII increased systolic blood pressure to the same extent in the MR-intact and ECMRKO mice when compared with untreated MR-intact and ECMRKO mice (Table S1 in the online-only Data Supplement). Plasma aldosterone levels were not different between control MR-intact and ECMRKO mice, and AngII treatment increased plasma aldosterone to the same degree in both mouse strains ( Figure 2B ). Plasma corticosterone was not changed in any group ( Figure 2D ).
Specific Deletion of the Endothelial MR Attenuated the Reduction in Cerebral Perfusion Induced by AngII Hypertension
We next determined the effect of AngII hypertension on cerebral perfusion. As expected, AngII hypertension reduced cerebral perfusion. We cannot confirm that eplerenone treatment improved perfusion because the vehicle for eplerenone ( Figure 1C ) also had a protective effect (Table S2 in the online-only Data Supplement). However, the changes in perfusion were prevented by EC-MR deletion ( Figure 1D ), which suggests that MR signaling in EC is involved in the process independent of changes in blood pressure. As the improvement in cerebral perfusion could be in part because of alterations in artery remodeling, we next examined the effect of MR inhibition on cerebral vascular structure in response to AngII hypertension. online-only Data Supplement). Conversely, AngII hypertension reduced wall stress in the PAs ( Figure 3E ), but not in the PCA ( Figure 4E) ; eplerenone treatment prevented the changes in PA wall stress. Wall stiffness was not changed by AngII hypertension in either vessel type ( Figure 3F ). Our data show that MR inhibition prevented inward remodeling ( Figures 3 and 4) without changing blood pressure (Table S1 in the online-only Data Supplement), suggesting that the MR contributes directly to the process of vascular remodeling in response to AngII hypertension independent of changes in blood pressure. The vehicle for eplerenone treatment did not improve AngII-induced artery remodeling ( Figure S4 in the online-only Data Supplement).
MR Antagonism Prevents
Endothelial MR Signaling Mediates PA and PCA Remodeling in AngII Hypertension
The benefits of MR antagonism were independent of blood pressure suggesting a potential direct effect on the vasculature. To explore this possibility, we determined the role of EC-MR signaling in the AngII-induced remodeling observed in the PAs and PCA. In the PAs, deletion of the MR, specifically from ECs, prevented the inward remodeling as ECMRKO mice treated with AngII had increased outer diameter ( Figure 5A As a result, there were no significant differences in cerebral vessel structure between MR-intact Sham-treated mice and ECMRKO littermates treated with AngII. EC-MR-specific deletion also prevented the change in wall:lumen ratio caused by AngII infusion ( Figure 5D ). However, the decreased wall stress caused by AngII hypertension in the MR intact+AngII was not reversed by EC-MR deletion in the ECMRKO+AngII mice ( Figure 5E ). This was contrary to the eplerenone study suggesting that changes in wall stress are mediated by MR outside the ECs, maybe in the VSMCs. As in the eplerenone study, wall stiffness ( Figure 5F ) and artery distensibility were not significantly different in either group ( Figure S7C in the online-only Data Supplement).
In the PCA, EC-MR deletion also prevented the AngII-induced remodeling as evidenced by the increase in the outer diameter ( Figure 6A ), lumen diameter ( Figure 6B ), vessel area ( Figure S8A in the online-only Data Supplement), lumen area ( Figure S8B in the onlineonly Data Supplement), and wall area ( Figure 6C ), but the changes were not as marked as in the PAs. In the PCA, EC-MR deletion did not prevent the increase in wall:lumen ratio caused by AngII hypertension ( Figure 6D ) as it had in the PA. Distensibility ( Figure S8C in the online-only Data Supplement) and artery wall stiffness ( Figure 6F) were not significantly changed by EC-MR deletion. EC-MR deletion did not reverse the reduced wall stress that was observed in MR intact+AngII mice ( Figure 6E ).
AngII Hypertension and MR Antagonism Change the mRNA Expression of MCP-1, IL-6, and MMP-2 in the PCA
To explore potential mechanisms by which the MR contributes to cerebral artery remodeling, we assessed the PCA mRNA expression for markers of inflammation, macrophage infiltration, oxidative stress, and MMPs (matrix metallaproteases) which have been previously associated with AngII-induced vascular remodeling. Importantly, MR and AngII receptor type 1 mRNA expression were unchanged in the PCA in response to AngII hypertension and eplerenone treatment ( Figure S9A and S9M in the online-only Data Supplement). Previous studies have shown that AngII hypertension increases the expression of MMP-2 in the aorta and in VSMC and that this is important for the process of arterial remodeling. 13, 14 Consistent with these previous findings, AngII treatment significantly increased the mRNA expression of MMP-2 in the PCA and this seems to be mediated, at least in part, by MR signaling as eplerenone prevented the increase ( Figure S9B in the onlineonly Data Supplement). AngII was also shown to increase the expression of MMP-9 in the aorta. 15 However, in the PCA, MMP-9 mRNA level was not significantly changed by AngII or eplerenone treatment ( Figure S9C in the online-only Data Supplement). MMP-12, produced by macrophages, may also play an important role in flow-induced artery remodeling. 16 In this study, we show that AngII hypertension increases the expression of MMP-12 mRNA in the PCA, but this does not seem to be mediated by MR signaling as MMP-12 expression was unchanged by eplerenone treatment ( Figure S9D in the online-only Data Supplement).
AngII has also been shown to increase the production of Nox2 (NADPH oxidase 2) 17 and Nox4 which has been shown to be regulated by the MR in human coronary arteries ECs. 18 However, in the PCA, the mRNA expression of Nox2 and Nox4 genes was not changed in response to AngII hypertension or MR inhibition ( Figure S9E and S9F in the online-only Data Supplement). Inflammatory markers including MCP-1 (monocyte chemoattractant protein 1) and IL-6 (interlukin-6) were increased in the PCA in response to AngII ( Figure S9G and S9H in the online-only Data Supplement). Other inflammatory markers including TNF-α (tumor necrosis factor-α) and the alternative macrophage marker YM1 (chitinase-like 3) tended to increase, but these changes were not statistically significant ( Figure S9I and S9J in the online-only Data Supplement). The mRNA expression of 2 collagen genes, Col2a1 and Col3a1, were not significantly changed by AngII hypertension or MR antagonism ( Figure S9K and S9L in the online-only Data Supplement). In summary, MR antagonism did not change the degree of AngII induction of inflammatory genes nor did AngII change the mRNA expression of Nox2. However, AngII significantly increased mRNA expression of MMP-2, and this was prevented by eplerenone.
Discussion
The novel findings in our study are that (1) in the absence of hypertension, cerebral artery structure does not depend on MR activation; and (2) the protective effect of MR inhibition in the cerebral circulation could be almost completely reproduced by EC-specific MR deletion suggesting that during AngII hypertension, EC-MR is necessary for hypertensive vascular remodeling and that cerebrovascular protection by MR inhibition is mediated by EC-MR. These findings enhance our understanding of the role of vascular MR signaling in cerebral artery remodeling.
PA and PCA Remodeling in Response to AngII Hypertension
AngII promotes the secretion of aldosterone by activation of the AngII receptor type 1 in the adrenal gland, and animal studies have shown that increases in circulating levels of AngII or aldosterone are associated with adverse vascular remodeling. 19, 20 As expected, AngII hypertension resulted in PA and PCA inward remodeling. The PAs also exhibited an increased wall:lumen ratio which has been shown to predict end organ damage. 21 Despite the increase in wall:lumen ratio, the wall area was reduced in the AngII-treated mice; this hypotrophic remodeling was an unexpected finding that will be discussed in more detail later. The AngII hypertension-associated changes in the mechanical properties were different in the 2 artery types supporting the need to study changes in the macro-and microcirculation separately. In the PAs, wall stress was decreased, but the same was not observed in the PCA. These differences could be associated with the location and innervation of these arteries and arterioles. To the best of our knowledge, this is the first time that AngII-dependent artery remodeling has been studied in the PAs and PCAs from the same animal; this is a strength of our study because all of the effects of circulating factors are the same.
A Role for MR in ECs in Hypertensive PA and PCA Remodeling
Our data further support previous studies, 5, 22, 23 indicating that MR activation contributes to inward hypotrophic remodeling in the PAs and PCAs during AngII hypertension. However, those previous studies did not identify the cell type involved in MR-mediated cerebral artery remodeling. In the current study, we show that EC-MR is necessary for the AngII-dependent hypertensive cerebral artery remodeling. The role of EC-MR was independent of changes in blood pressure or basal cerebral vessel structure before exposure to AngII hypertension suggesting a direct role for EC-MR in the response of the cerebral vasculature to hypertension induced by AngII. Whether EC-MR contributes to cerebral remodeling in response to hypertension caused by a distinct mechanism remains to be explored. Because hypertension is predominantly a disorder of the elderly and AngII signaling increases with aging and contributes to the rise in blood pressure with aging, 24 this mechanism has important implications for the growing aging population in which dementia and stroke are important causes of morbidity and mortality.
Possible Mechanisms for the EC-MR-Mediated Remodeling
This study implicates an important role for EC-MR in cerebral artery remodeling; however, the mechanisms downstream of MR activation have not been identified. Additional in vivo studies that are beyond the scope of this study will be required to identify the mechanism because the remodeling process likely requires exposure to hypertension and circulating factors and hence cannot be reproduced in vitro. Previous studies have implicated oxidative stress, inflammation, and extracellular matrix remodeling in AngIIinduced artery remodeling. 17, 19, 20, [25] [26] [27] In the PCAs, we found that AngII hypertension increases the mRNA expression of MCP-1 and IL-6 suggesting a possible role for these cytokines in the remodeling process. However, these changes in cytokine mRNA were not mediated by MR activation because eplerenone did not reduce MCP-1 or IL-6 mRNA levels. We did not observe any changes in the gene expression of collagen, but AngII hypertension increased the mRNA expression of MMP-2 that was prevented by eplerenone treatment. The increase in MMP-2 mRNA seems to be specific because no changes in MMP-9 and MMP-12 mRNA were observed. These observations suggest the possibility that changes in MMP-2 induced by AngII hypertension could involve MR signaling and contribute to vascular remodeling during AngII hypertension; however, additional studies are needed to confirm this potential mechanism. Although previous studies link aldosterone production to MMP-2 activity, 28 other studies have also shown that AngII increased MMP-9 production to mediate pial arteriole remodeling 29 confirming regional heterogeneity in remodeling mechanisms that the regulation of the MMPs is complex and that MMP-2 might not be the only MMP regulating artery wall structure. 30 Studies from our laboratory support a role for MMP-2 in the hypertensive cerebral artery remodeling process as doxycycline, an MMP-2 inhibitor, prevented cerebral artery remodeling in hypertensive rats. 31 A limitation in our study is that we could only measure changes in mRNA expression in the PCA, but not in PA because of limited tissue availability.
Differences in the Role of EC-MR in Small Cerebral
Arterioles PA Versus PCA
The mechanical properties of the PAs and PCAs were differentially affected by AngII hypertension. In the PAs, the decrease in diameter was accompanied by a reduction in wall stress that suggests that these arterioles remodeled to maintain wall stress within a normal range during hypertension. The changes in wall stress were prevented in the hypertensive mice by eplerenone treatment, but not by EC-MR deletion; this suggests that the effect of eplerenone on wall stress might be mediated by MR in VSMC or some other cell type. However, this is speculative, and additional studies with VSMC-specific MR deletion will need to be conducted to confirm this possibility.
EC-MR Signaling Contributes to Changes in Cerebral Blood Flow in Response to AngII Hypertension
EC-specific MR deletion enhanced cerebral blood flow in mice with AngII hypertension, suggesting that MR inhibition in the endothelium is sufficient to protect from impaired cerebral blood flow in this hypertension model. Previous studies have shown that artery structure changes are associated with changes in perfusion. 3, 32 Although the changes in artery structure correlate well with the reduction in blood flow, it is important to note that AngII could also negatively impact endothelium-dependent vasodilation and that other factors could also contribute to decreased blood flow. [33] [34] [35] [36] [37] Previous studies demonstrated that EC-MR deletion protects the mesenteric vasculature from endothelial dysfunction caused by AngII hypertension. 10 Future studies will examine whether this is also occurring in the cerebral vasculature in addition to the structural benefits of EC-MR deletion. Because EC-MR deletion preserved cerebral blood flow in the setting of AngII hypertension and AngII is an important driver of hypertension in the elderly, 24 ,38 future studies could explore whether this could have implications for improving cognitive function and stroke outcomes.
Some limitations of our study must be acknowledged. First, vascular endothelial-cadherin is also expressed in a small compartment of hematopoietic cells. All of the studies were done in male mice, so we did not assess possible sex differences. Although we implicate EC-MR signaling in cerebral artery remodeling in AngII hypertension, we have not determined the detailed molecular mechanism. Our studies suggest that IL-6, MMP-2, and MMP-9 are involved in the AngIIinduced hypertensive remodeling process, and the data we have thus far suggest that MMP-2 could be a critical mediator of the MR-dependent remodeling, but additional studies are required to verify this. Another limitation is that the vehicle for eplerenone improved cerebral blood flow; however, it did not alter artery structure. This disconnect between structure and flow could be a consequence of the technique used to assess blood flow. The laser in the Pim3 system we used has a penetration of ≈1 mm; with the skull intact, it is likely that we are measuring only the blood flow on the surface of the brain and not the flow in the PAs. We have not studied remodeling of the pial arteries so it is unclear if changes in their structure can explain the differences in cerebral blood flow. However, the fact that in the AngII-treated ECMRKO mice the perfusion was improved suggests that EC-MR signaling is involved in the changes in perfusion. Cerebral blood flow was measured in mice anesthetized with isoflurane which is a vasodilator, 32, 39 we also did not measure blood gases, while the animals were under anesthetic, which is a limitation. However, the comparisons were made with appropriate controls also exposed to isoflurane. Nonetheless, additional studies using alternative methods are warranted. We recognize differences in dilator responses to isoflurane are possible between the groups, but this is a limitation of all studies of this type.
We only assessed changes in gene expression of the PCA because the limited tissue from the PAs did not allow accurate measurement of changes in gene expression. We measured blood pressure using tail-cuff plethysmography; we recognize that telemetry blood pressure measurements are generally considered to be more accurate than tail-cuff. The increase in blood pressure after AngII infusion was consistent in every mouse, and recent studies show that tail-cuff blood pressure measurements in AngII-treated mice are very similar to those obtained by telemetry in an undisturbed mouse. 40 The role of the MR in VSMC in hypertensive artery remodeling should also be considered as VMSC MR contributes to myogenic tone and arterial remodeling in response to carotid injury and to vascular stiffness in response to aldosterone/salt-induced hypertension. 41, 42 Future studies will also consider whether there are EC-MR-mediated changes in endothelium-dependent vasodilation and myogenic tone in cerebral vessels in response to hypertension. Previous studies have shown that PAs and PCA from hypertensive rats have increased myogenic tone compared with normotensive Wistar Kyoto rats.
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Perspectives
Our study fills a gap in our knowledge of how MR signaling mediates hypertensive remodeling in arterioles in the microcirculation and arteries in the pial circulation in the brain. Hypertension has been linked to cerebrovascular diseases such as ischemic stroke and the development of vascular dementia. 44 , 45 We used EC-specific MR knockout mice to show, for the first time, the role played by the EC-MR in cerebral artery remodeling and that MR inhibition or EC-MR deletion improved cerebral blood flow without changing blood pressure. Identification of the cell-specific actions of aldosterone and MR signaling could allow us to better define the downstream mechanisms of MR-mediated cerebral artery remodeling in hypertension. This could contribute to the development of better therapeutic approaches to improve cerebrovascular health in hypertensive patients, a rapidly growing concern in our aging population.
